دورية أكاديمية
أعرض في EDS

Arecoline induced cell cycle arrest, apoptosis, and cytotoxicity to human endothelial cells.

التفاصيل البيبلوغرافية
العنوان: Arecoline induced cell cycle arrest, apoptosis, and cytotoxicity to human endothelial cells.
المؤلفون: Tseng SK; Graduate Institute of Clinical Dentistry, National Yang-Ming University, No. 155, Sec. 2, Li-Nong St, Beitou District, Taipei, Taiwan., Chang MC, Su CY, Chi LY, Chang JZ, Tseng WY, Yeung SY, Hsu ML, Jeng JH
المصدر: Clinical oral investigations [Clin Oral Investig] 2012 Aug; Vol. 16 (4), pp. 1267-73. Date of Electronic Publication: 2011 Aug 17.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 9707115 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1436-3771 (Electronic) Linking ISSN: 14326981 NLM ISO Abbreviation: Clin Oral Investig
أسماء مطبوعة: Publication: Berlin : Springer-Verlag
Original Publication: Berlin : Springer, c1997-
مواضيع طبية MeSH: Arecoline/*toxicity , Cholinergic Agonists/*toxicity , Endothelial Cells/*drug effects, Apoptosis/drug effects ; Cell Adhesion/drug effects ; Cell Culture Techniques ; Cell Cycle/drug effects ; Cell Line ; Cell Proliferation/drug effects ; Cell Shape/drug effects ; Cell Survival/drug effects ; Coloring Agents ; DNA/analysis ; Endothelium, Vascular/cytology ; Flow Cytometry ; G1 Phase/drug effects ; Humans ; Interphase/drug effects ; Propidium ; Resting Phase, Cell Cycle/drug effects ; Tetrazolium Salts ; Thiazoles ; Time Factors
مستخلص: Betel quid (BQ) chewing is a common oral habit in South Asia and Taiwan. BQ consumption may increase the risk of oral squamous cell carcinoma (OSCC), oral submucous fibrosis (OSF), and periodontitis as well as systemic diseases (atherosclerosis, hypertension, etc.). However, little is known about the toxic effect of BQ components on endothelial cells that play important roles for angiogenesis, carcinogenesis, tissue fibrosis, and cardiovascular diseases. EAhy 926 (EAHY) endothelial cells were exposed to arecoline, a major BQ alkaloid, for various time periods. Cytotoxicity was estimated by 3-(4, 5- dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay. The cell cycle distribution of EAHY cells residing in sub-G0/G1, G0/G1, S-, and G2/M phases was analyzed by propidium iodide staining of cellular DNA content and flow cytometry. Some EAHY cells retracted, became round-shaped in appearance, and even detached from the culture plate after exposure to higher concentrations of arecoline (> 0.4 mM). At concentrations of 0.4 and 0.8 mM, arecoline induced significant cytotoxicity to EAHY cells. At similar concentrations, arecoline induced G2/M cell cycle arrest and increased sub-G0/G1 population, a hallmark of apoptosis. Interestingly, prolonged exposure to arecoline (0.1 mM) for 12 and 21 days significantly suppressed the proliferation of EAHY cells, whereas EAHY cells showed adaptation and survived when exposed to 0.05 mM arecoline. These results suggest that BQ components may contribute to the pathogenesis of OSF and BQ chewing-related cardiovascular diseases via toxicity to oral or systemic endothelial cells, leading to impairment of vascular function. During BQ chewing, endothelial damage may be induced by areca nut components and associate with the pathogenesis of OSF, periodontitis, and cardiovascular diseases.
References: Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v14-5. (PMID: 18784128)
J Dent Res. 1994 May;73(5):1043-9. (PMID: 8006230)
Toxicology. 2008 Jul 30;249(2-3):230-7. (PMID: 18585839)
Science. 1996 Dec 6;274(5293):1664-72. (PMID: 8939848)
Arch Oral Biol. 1986;31(1):45-9. (PMID: 3458437)
J Oral Pathol Med. 1992 Jul;21(6):261-4. (PMID: 1501158)
Biol Res. 2009;42(3):377-89. (PMID: 19915746)
Oral Oncol. 2007 May;43(5):424-30. (PMID: 17258497)
Proc Natl Acad Sci U S A. 1983 Jun;80(12):3734-7. (PMID: 6407019)
J Cell Sci. 2000 Feb;113 ( Pt 3):471-82. (PMID: 10639334)
IARC Monogr Eval Carcinog Risks Hum. 2004;85:1-334. (PMID: 15635762)
Am Heart J. 2005 Jun;149(6):950-4. (PMID: 15976771)
Carcinogenesis. 2001 Sep;22(9):1527-35. (PMID: 11532876)
Addict Biol. 2002 Jan;7(1):115-25. (PMID: 11900631)
Free Radic Biol Med. 2002 May 1;32(9):860-71. (PMID: 11978487)
J Biol Chem. 2004 Dec 3;279(49):50676-83. (PMID: 15375172)
Semin Thromb Hemost. 1996;22(4):309-15. (PMID: 8944415)
Biomaterials. 2010 Nov;31(32):8164-71. (PMID: 20673999)
Chem Res Toxicol. 2006 Jun;19(6):818-27. (PMID: 16780361)
J Oral Pathol Med. 2001 Apr;30(4):200-5. (PMID: 11302238)
Biochem Pharmacol. 2007 Feb 15;73(4):561-73. (PMID: 17123469)
Environ Mol Mutagen. 2009 Jun;50(5):367-74. (PMID: 19197989)
J Dent Res. 1994 May;73(5):1050-5. (PMID: 8006231)
Am J Clin Nutr. 2008 Jan;87(1):70-8. (PMID: 18175739)
Genome Dyn. 2006;1:131-148. (PMID: 18724058)
J Anal Toxicol. 2010 Jul-Aug;34(6):325-31. (PMID: 20663285)
Carcinogenesis. 2000 Jul;21(7):1365-70. (PMID: 10874015)
J Oral Pathol Med. 1994 Apr;23(4):145-8. (PMID: 8046651)
Expert Opin Biol Ther. 2003 Oct;3(7):1105-20. (PMID: 14519075)
Carcinogenesis. 2003 Aug;24(8):1301-15. (PMID: 12807728)
Am J Clin Nutr. 2008 May;87(5):1204-11. (PMID: 18469240)
J Periodontal Res. 2009 Oct;44(5):673-82. (PMID: 19364390)
In Vitro Cell Dev Biol. 1990 Dec;26(12):1167-72. (PMID: 2079463)
Toxicology. 2006 Mar 15;220(2-3):81-9. (PMID: 16413651)
Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2570-81. (PMID: 20713654)
J Oral Pathol Med. 2010 Jul;39(6):465-9. (PMID: 20412403)
Eur J Pharmacol. 1987 Jan 28;134(1):61-7. (PMID: 3556399)
Oral Oncol. 2001 Sep;37(6):477-92. (PMID: 11435174)
Ann Acad Med Singap. 2004 Jul;33(4 Suppl):31-6. (PMID: 15389304)
Toxicology. 2008 Jan 14;243(1-2):1-10. (PMID: 17997002)
Carcinogenesis. 1985 Feb;6(2):295-303. (PMID: 3971493)
Oral Oncol. 2010 Apr;46(4):255-62. (PMID: 20138568)
Biomed Pharmacother. 2009 Mar;63(3):171-9. (PMID: 18823739)
Pathol Oncol Res. 1999;5(1):49-55. (PMID: 10079379)
Hunan Yi Ke Da Xue Xue Bao. 2000 Feb 28;25(1):55-7. (PMID: 12212249)
Arzneimittelforschung. 1976;26(5):951-6. (PMID: 786304)
Addict Biol. 2002 Jan;7(1):103-10. (PMID: 11900629)
Ann Emerg Med. 1999 Aug;34(2):238-43. (PMID: 10424931)
Oral Oncol. 2010 Jul;46(7):553-8. (PMID: 20538504)
J Hepatol. 2007 May;46(5):927-34. (PMID: 17391799)
Autoimmun Rev. 2010 Oct;9(12):830-4. (PMID: 20678595)
المشرفين على المادة: 0 (Cholinergic Agonists)
0 (Coloring Agents)
0 (Tetrazolium Salts)
0 (Thiazoles)
36015-30-2 (Propidium)
4ALN5933BH (Arecoline)
9007-49-2 (DNA)
EUY85H477I (thiazolyl blue)
تواريخ الأحداث: Date Created: 20110818 Date Completed: 20130213 Latest Revision: 20211020
رمز التحديث: 20240513
DOI: 10.1007/s00784-011-0604-1
PMID: 21847594
قاعدة البيانات: MEDLINE
الوصف
تدمد:1436-3771
DOI:10.1007/s00784-011-0604-1